Topical delivery of enoxaparin using nanostructured lipid carrier

Journal of Microencapsulation

Volumn 30, Issue 7, 2013, Pages 709-715

  Jain, Aakanchha ^a   Mehra, Neelesh Kumar ^a   Nahar, Manoj ^a   Jain, N K ^a  

^a DR H S GOUR UNIVERSITY   (India)

Author keywords

Diffusion; Enoxaparin; Fluorescence microscopy; Irritation permeation; Nanostructured lipid carriers; Permeation; Skin

Indexed keywords

CARBOPOL 934; ENOXAPARIN; LIPID; NANOCARRIER; NANOSTRUCTURED LIPID CARRIER; OLEIC ACID; POLYSORBATE 80; TRISTEARIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG STABILITY; FEMALE; FLUORESCENCE MICROSCOPY; IN VITRO STUDY; IN VIVO STUDY; MALE; MORPHOLOGY; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; RAT; SKIN IRRITATION; SKIN PERMEABILITY; THROMBOSIS; ZETA POTENTIAL;

ADMINISTRATION, CUTANEOUS; ANIMALS; ANTICOAGULANTS; DRUG CARRIERS; ENOXAPARIN; FEMALE; LIPID METABOLISM; LIPIDS; MALE; NANOSTRUCTURES; RATS; SKIN; SKIN ABSORPTION;

EID: 84885345341     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652048.2013.778908     Document Type: Article

References (40)

1. Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A, Dietrich-Neto F. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. New Eng J Med, 2002;246(13):975-80.
2. Betz G, Nowbakht P, Imboden R, Imanidis G. Heparin penetration into and permeation through human skin from aqueous and liposomal formulation in-vitro. Int J Pharm, 2001;228(1-2):147-59.
3. Bhaskar K, Anbu J, Ravichandiran V, Venkateswarlu V, Rao YM. Lipid nanoparticles for transdermal delivery of flurbiprofen: Formulation, in vitro, ex vivo and in vivo studies. Lipids Health Dis, 2009;8:1-15.
4. Bunjes H, Westesen K, Koch MHJ. Crystallization tendency and polymorphic transitions in triglyceride nanoparticles. Int J Pharm, 1996;129:159-73.
5. Draize J, Woodward G, Calvery HO. Methods for the study of irritation and toxicity of substances topically applied to skin and mucuos membranes. J Pharmacol Exp Ther, 1944;82:377-90.
6. Gafe F, Wohlrab W, Neubert RH, Brandsch M. Transport of biotin in human keratinocytes. J Investigat Dermatol, 2003;120(3):428-33.
7. Greer IA, Nelson-Piercy C. Low molecular weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: A systematic review of safety and efficacy. Blood, 2005; 106:401-7.
8. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficiency, and safety. Chest, 2001; 119(1):64S-94S.
9. Hofmann T. Clinical application of enoxaparin. Exp Rev Cardiovasc Ther, 2004;2(3):321-37.
10. Hu FQ, Jiang SP, Du YZ, Yuan H, Ye YQ, Zeng S. Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system. Colloids Surfaces B, 2005; 45(3-4):167-73.
11. Hu FQ, Jiang SP, Du YZ, Yuan H, Ye YQ, Zeng S. Preparation and characteristics of monostearin nanostructured lipid carriers. Int J Pharm, 2006;314:83-89.
12. Investigational New Drug Application US Department of Health and Human Services. [Online] Available at: http://www.hhs.gov. Accessed 13 March 2013.
13. Jain S, Jain P, Umamaheswari RB, Jain NK. Transfersomes-A novel vesicular carrier for enhanced transdermal delivery: Development, characterization and performance evaluation. Drug Dev Ind Pharm, 2003;29:1013-26.
14. Jain S, Umamaheshwari RB, Bhadra D, Jain NK. Ethosomes: A novel vesicular carrier for enhanced transdermal delivery of an anti HIV agent. Ind J Pharm Sci, 2004;66(1):72-81.
15. Jenning V, Thünemann AF, Gohla SH. Characterization of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int J Pharm, 2000;199(2):167-77.
16. Jores K, Mehnert W, Drechsler M, Bunjes H, Johann C, Mader K. Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy. J Control Release, 2004;95(2):217-27.
17. Jores K, Mehnert W, Mader K. Physicochemical investigations of solid lipid nanoparticles and oil loaded solid lipid nanoparticles: A nuclear magnetic resonance and electron spin resonance study. Pharm Res, 2003;20(8)1274-83.
18. Khurana S, Utreja P, Tiwary AK, Jain NK, Jain, S. Nanostructured lipid carriers and their application in drug delivery. Int J Biomed Eng Tech, 2009;2(2):152-71.
19. Levy JH, Tanaka KA, Hursting MJ. Reducing thrombotic complications in the perioperative setting: An update on heparin induced thrombo-cytopenia. Anesth Analg, 2007;105(3):570-82.
20. Maaßen S, Schwarz C, Mehnert W, Lucks JS, Yunis-Specht F, Muller BW, et al. Comparison of cytotoxicity between polyester nanoparticles and solid lipid nanoparticles (SLN). Proceedings of International Symposia Controlled Release Bioact. Material, 1993;20:490-1.
21. Mehnert W, Mader K. Solid lipid nanoparticles: Production, characterization and applications. Adv Drug Deliv Rev, 2001;47(2-3):165-96.
22. Muller RH, Lucks JS. Arzneistofftrager aus festen Lipidteilchen, Feste Lipidnanospharen (SLN). European Patent No. 0605497, 1996.
23. Muller RH, Maaßen S, Werghens H, Specht F, Lucks JS. Cytotoxicity of magnetite loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles (SLN). Int J Pharm, 1996;138:85-94.
24. Muller RH, Petersen RD, Hommoss A, Pardeike J. Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv Drug Deliv Rev, 2007;59(6):522-30.
25. Sanson BJ, Lensing AW, Prins MH, Ginsberg JS, Barkagan ZS, Lavenne-Pardonge E, Brenner B, Dulitzky M, Nielsen JD, Boda Z, et al. Safety of low-molecular-weight heparin in pregnancy: A systematic review. Thromb Haemost, 1999;81(5):668-72.
26. Saupe A, Gordon KC, Rades T. Structural investigations on nanoemul-sions, solid lipid nanoparticles and nanostructured lipid carriers by cryo-field emission scanning electron microscopy and Raman spec-troscopy. Int J Pharm, 2006;314(1):56-62.
27. Schaefer H, Lademann J. The role of follicular penetration. A differential view. Skin Pharmacol App Skin Physiol, 2001;14(1):23-27.
28. Song YK, Kim CK. Topical delivery of low molecular weight heparin with surface charged flexible liposomes. Biomaterials, 2006;27: 271-80.
29. Souto EB, Wissing SA, Barbosa CM, Muller RH. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm, 2004;278(1):71-77.
30. Sznitowska M, Janicki S. Percutaneous absorption of heparin: A critical review of experimental results. Pol Merkuriusz Lek, 2000;7:58-63.
31. Sznitowska M, Janicki S, Williams AC. Intracellular or intercellular localizationof the polar pathway of penetration across stratum corneum. Pharm Sci, 1998;87(9):1109-14.
32. Teeranachaideekul V, Boonme P, Souto EB, Muller RH, Junyaprasert VB. Influence of oil content on physicochemical properties and skin distribution of Nile red-loaded NLC. J Control Release, 2008; 128(2):134-41.
33. Teeranachaideekul V, Souto EB, Junyaprasert VB, Müller RH. Cetyl palmitate-based NLC for topical delivery of Coenzyme Q10: Development, physicochemical characterization and in-vitro release studies. Eur J Pharm Biopharm, 2007;67:141-48.
34. Ulrich AS. Biophysical aspects of using liposomes as delivery vehicles. Biosci Rep, 2002;22:129-50.
35. Wang JX, Sun X, Zhang ZR. Enhanced brain targeting by synthesis of 3, 5-dioctanoyl-5-fluoro-2-deoxyuridine and incorporation into solid lipid nanoparticles. Eur J Pharm Biopharm, 2002;54(3):285-90.
36. Warwick D, Bannister GC, Glew D, Mitchelmore A, Thornton M, Peters TJ, Brookes S. Perioperative low-molecular-weight heparin. Is it effective and safe? J Bone Joint Surg, 1995;77-B(5):715-19.
37. Weiner AL. Liposomes for protein delivery: Selecting manufacture and development processes. Immunomethods, 1994;4(3):201-9.
38. Xia Q, Saupe A, Muller RH, Souto EB. Nanostructured lipid carriers as novel carrier for sunscreen formulations. Int J Cosmet Sci, 2007; 29(6):473-82.
39. Zhang J, Purdon CH, Smith EW. Solid lipid nanoparticles for topical drug delivery. Am J Drug Del, 2006;4(4):215-20.
40. Zhao XL, Yang CR, Yang KL, Li KX, Hu H-Y, Chen DW. Preparation and characterization of nanostructured lipid carriers loaded traditional Chinese medicine, zedoary turmeric oil. Drug Dev Ind Pharm, 2010; 36(7):773-80.